Back to search results

Observational Study for Pancreatic Cancer Screening in High-Risk Individuals

This observational study is looking at how well imaging tests, like endoscopic ultrasound (EUS) or MRI, can find early signs of pancreatic cancer in people who have a higher risk due to certain inherited gene changes. These gene changes include BRCA1, BRCA2, ATM, or PALB2. You would already be undergoing these imaging tests as part of your regular care, typically every 12 months. The study also involves collecting blood samples for research. Researchers want to see if these screening methods can help identify pancreatic lesions (abnormal areas) in people with these genetic mutations over a 10-year period. The study is currently unclear on its recruitment status and aims to enroll 200 participants.

Study design
This is an observational study that aims to enroll 200 participants. It is not a randomized or blinded study.
What's involved
You would undergo regular pancreatic cancer screening with endoscopic ultrasound or MRI, typically every 12 months. Up to 40mL of blood may also be collected at each screening examination.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 10 years, suggesting a long-term follow-up.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02478892

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Recruiting
Not specifiedAges 18+Observational
Abramson Cancer Center at Penn Medicine
~200 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomenBlood sample collection for research

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.
Measured over 10 years

Conditions

Pancreatic Cancer

Explore related trials

Pancreatic CarcinomaATM GeneBRCA1 GeneBRCA2 GenePartner and Localizer of BRCA2

Where it's being run

1 sites across 1 states
Pennsylvania1

Who to contact

Bryson Katona, MD
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>= 18
Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
If no history of PDAC in a first or second degree relative, age \>= 50
If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer

What this trial measures

  • identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.10 years

    The primary objective of the study is the observational screening of patients with BRCA1/2, ATM, or, PALB2 mutations for pancreatic neoplastic lesions, to assess for both the feasibility of this approach in this high risk population as well as to better establish the incidence of these lesions in this cohort.